Sarepta (SRPT) calls active after FDA approves eteplirsen
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) September and October 43 calls are active after a post to the website of the FDA indicated that the regulator granted approval for eteplirsen, the company's treatment of Duchenne muscular dystrophy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Target of Cautious Article
- Apple (AAPL) October weekly 117.5 straddle priced for movement of 4.4% into Q4
- Apple (AAPL) October weekly volatility increases on more puts than calls into Q4
Create E-mail Alert Related CategoriesOptions, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!